METASTATIC CANCER

This study tested a new drug called ozuriftamab vedotin in 42 people with head and neck cancer that had come back or spread. The goal was to see if the drug could shrink tumors and to check for side effects. The study is now complete, and results will help decide if the drug shou…

This study tested whether adding a third drug, ipilimumab, to a two-drug combination (atezolizumab and bevacizumab) helps people with advanced liver cancer live longer or have better tumor shrinkage. 229 participants received either the two-drug or three-drug treatment for up to …

This early-phase study tested a new treatment called NG-350A, a virus designed to activate immune cells inside tumors, combined with the immunotherapy drug pembrolizumab. It involved 14 people with advanced epithelial cancers that had stopped responding to standard treatments. Th…

This study tested an experimental drug called ART4215 in 93 people with advanced or metastatic solid tumors (cancers that have spread). The goal was to find a safe dose and see how well it works alone or combined with other cancer drugs (talazoparib or niraparib). Participants ha…

This early-stage study tested a new treatment called VE800 combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goal was to see if the combination is safe and whether it can shrink …

This early-phase study tested the safety of combining several cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for each combination to use in later studies. Participant…

This study tested a new, precise radiation treatment called SABR in 13 adults with metastatic cancer that had spread to more than 10 spots in the body. The goal was to see if it is safe and to find the best dose. Researchers hope this approach can better control cancer while caus…

This study tested a drug called sunitinib in 21 people with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors. Sunitinib works by blocking enzymes that help cancer cells grow and by cutting off blood flow to tumors. The study wa…

This early-phase study tested a new experimental drug called HMBD-002, alone or with another cancer drug (pembrolizumab), in 48 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see …

This early-stage study tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had come back or stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers monitored side effects and how the dr…

This early-phase study tested a combination of two drugs, cabozantinib and TAS-102, in 15 people with metastatic colorectal cancer that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The study is complete and h…

This study tested a single, high-dose radiation treatment on people with cancer that has spread to only a few spots (1 to 5). The goal was to see if this approach can control or eliminate those spots and help people live longer without the cancer growing back. The treatment is fo…

This early-stage study tested an experimental drug called CTX-471, given alone or with another immunotherapy (pembrolizumab), in 100 adults with advanced solid tumors that had stopped responding to standard PD-1/PD-L1 inhibitors. The main goal was to check safety and find the rig…

This early-phase study tested a new immune cell treatment called PD-L1 t-haNK in 16 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to check the treatment's safety, find the best dose, and see if it could shrink tumors. Th…

This study looked at whether adding a precise type of radiation (SBRT) to standard immunotherapy could shrink tumors better than immunotherapy alone in people with advanced cancer that has spread. A total of 106 patients with metastatic cancer took part. The main goal was to see …

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and check for side effects, while also looking at how the drug moves through…

This study looked at how safe and effective two targeted drugs, trastuzumab deruxtecan and sacituzumab govitecan, are for people with advanced breast cancer. Researchers reviewed medical records of 312 patients who had already tried other treatments. The goal was to see side effe…

This study tested whether adding a chemotherapy-like drug (thiopurine) to an immunotherapy (Atezolizumab) could help shrink advanced solid tumors that have spread. 18 adults with metastatic cancer that had no standard cure took part. The goal was to find the safest dose and see i…

This study tested whether giving a booklet with suggested questions helps cancer patients or their families ask more during palliative care visits. 121 adults with metastatic cancer and limited life expectancy took part. The goal was to see if the booklet encourages people to ask…

This study looked at whether a special organized consultation when leaving the hospital helps people with metastatic cancer. 667 patients were split into two groups: one got the usual discharge instructions, and the other had a meeting with their doctor and a specialist to plan t…

This study tested a program called ED GOAL that helps older adults with serious illnesses like heart failure or cancer talk about their care wishes while in the emergency department. Researchers worked with 141 patients to see if the program increased their engagement in advance …